ESRD Clinical Trial
Official title:
Bringing Care to Patients: A Patient-Centered Medical Home for Kidney Disease
This study will implement and evaluate a patient-centered medical home for kidney disease (PCMH-KD) compared to the usual model of dialysis care. Patients will be observed for an initial baseline period under the usual care model and then the usual dialysis care team will be expanded to include a pharmacist, health promoter, nurse coordinator and a primary care doctor. Outcomes of interest will be assessed at baseline and then every 6 months after the PCMH-KD intervention commences.
Patients with end-stage renal disease (ESRD), have unique and complex care needs associated
with renal disease and common comorbidities (e.g., diabetes, hypertension), and under the
current care model, receive fragmented care from multiple providers at multiple locations.
ESRD patients typically spend three to five hours undergoing dialysis three days a week.
Scheduling and traveling to other appointments are difficult to manage, increase patient and
caregiver burden, and reduce patients' quality of life. These challenges keep many ESRD
patients from receiving care for other conditions outside of the dialysis setting, resulting
in higher rates of complications, and emergent healthcare use.
The patient-centered medical home (PCMH) model has been proposed as a solution to patients
with complex needs such as those with ESRD. The purpose of this project is to compare a PCMH
model of care with the usual care of ESRD patients and their caregivers. We propose to
enhance the usual care team for ESRD patients by providing a primary care doctor in the
context of regularly scheduled dialysis sessions and by adding health promoters to help
support patients and their caregivers. Patient and family stakeholders and care team members
will assist in the design and refinement of the PCMH model.
We plan to implement this model at the University of Illinois Hospital and Health Sciences
System (UIHS) dialysis center and a local Fresenius Medical Care dialysis center. Patients
receiving dialysis at participating centers will receive an initial comprehensive care visit
followed by ongoing care from a multispecialty provider team during the patients' regularly
scheduled dialysis visits. Each patient's care team will include a kidney doctor, a primary
care doctor, a nurse coordinator, a dialysis nurse, a dietician, a pharmacist, a social
worker, and a health promoter. The primary care doctor will be available in the dialysis
clinic to provide general and preventive care to the patient before or after dialysis
sessions. This doctor would also coordinate care with other specialists/clinicians on the
patient's care team. The trained, bilingual (English/Spanish) health promoter will assist
with making and rescheduling appointments, obtaining transportation, and reinforcing
education components.
We expect that this approach will increase patient access to care for other conditions and
will increase care coordination and communication among members of the patient's care team.
These improvements could potentially increase the likelihood of preventing complications or
identifying problems earlier and allow for a more successful treatment. We expect that this
enhanced care team will reduce emergency room visits and hospitalizations for dialysis
patients. In addition, we anticipate that the addition of health promoters to the clinical
team will help support and educate patients and their caregivers and as a result, patient
quality of life will improve and caregiver burden may be reduced.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT03943212 -
The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis
|
N/A | |
Completed |
NCT03456648 -
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
|
Phase 2 | |
Completed |
NCT01252771 -
Phosphate Kinetic Modeling 2
|
Phase 4 | |
Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
Completed |
NCT00294502 -
Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia
|
Phase 4 | |
Completed |
NCT05011136 -
Physician Reimbursement Home Patients
|
||
Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
Completed |
NCT02278562 -
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
|
Phase 2 | |
Completed |
NCT01424787 -
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
|
N/A | |
Terminated |
NCT00580762 -
Bariatric Surgery for ESRD Patients vs Control
|
N/A | |
Recruiting |
NCT05339139 -
SAfety of Regional Citrate Anticoagulation (SARCA Study)
|
Phase 3 | |
Completed |
NCT03242343 -
VasQ External Support for Arteriovenous Fistula
|
N/A | |
Recruiting |
NCT05309785 -
Safety and Efficacy of Canagliflozin in Advanced CKD
|
Phase 4 | |
Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
Not yet recruiting |
NCT02596386 -
Examination of Potassium Levels in Saliva in ESRD Patients
|
N/A | |
Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A | |
Completed |
NCT03326583 -
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
|
Phase 2 |